Literature DB >> 9535769

Glycogen storage disease type II: identification of four novel missense mutations (D645N, G648S, R672W, R672Q) and two insertions/deletions in the acid alpha-glucosidase locus of patients of differing phenotype.

M L Huie1, S Tsujino, S Sklower Brooks, A Engel, E Elias, D T Bonthron, C Bessley, S Shanske, S DiMauro, Y I Goto, R Hirschhorn.   

Abstract

Glycogen storage disease type II (GSDII), an autosomal recessive myopathic disorder, results from deficiency of lysosomal acid alpha-glucosidase. We searched for mutations in an evolutionarily conserved region in 54 patients of differing phenotype. Four novel mutations (D645N, G448S, R672W, and R672Q) and a previously described mutation (C647W) were identified in five patients and their deleterious effect on enzyme expression demonstrated in vitro. Two novel frame-shifting insertions/deletions (delta nt766-785/insC and +insG@nt2243) were identified in two patients with exon 14 mutations. The remaining three patients were either homozygous for their mutations (D645N/D645 and C647W/C647W) or carried a previously described leaky splice site mutation (IVS1-13T-->G). For all patients "in vivo" enzyme activity was consistent with clinical phenotype. Agreement of genotype with phenotype and in vitro versus in vivo enzyme was seen in three patients (two infantile patients carrying C647W/C647W and D645N/+insG@nt2243 and an adult patient heteroallelic for G648S/IVS1-13T-->G). Relative discordance was found in a juvenile patient homozygous for the non-expressing R672Q and an adult patient heterozygous for the minimally expressing R672W and delta nt766-785/+insC. Possible explanations include differences in in vitro assays vs in vivo enzyme activity, tissue specific expression with diminished enzyme expression/stability in fibroblasts vs muscle, somatic mosaicism, and modifying genes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9535769     DOI: 10.1006/bbrc.1998.8255

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations.

Authors:  Sueli M Oba-Shinjo; Roseli da Silva; Fernanda G Andrade; Rachel E Palmer; Robert J Pomponio; Kristina M Ciociola; Mary S Carvalho; Paulo S Gutierrez; Gilda Porta; Carlo D Marrone; Verônica Munoz; Anderson K Grzesiuk; Juan C Llerena; Célia R Berditchevsky; Claudia Sobreira; Dafne Horovitz; Thamine P Hatem; Elizabeth R C Frota; Rogerio Pecchini; João Aris Kouyoumdjian; Lineu Werneck; Veronica M Amado; José S Camelo; Robert J Mattaliano; Suely K N Marie
Journal:  J Neurol       Date:  2009-07-09       Impact factor: 4.849

2.  Homozygosity for multiple contiguous single-nucleotide polymorphisms as an indicator of large heterozygous deletions: identification of a novel heterozygous 8-kb intragenic deletion (IVS7-19 to IVS15-17) in a patient with glycogen storage disease type II.

Authors:  Maryann L Huie; Kwame Anyane-Yeboa; Edwin Guzman; Rochelle Hirschhorn
Journal:  Am J Hum Genet       Date:  2002-02-19       Impact factor: 11.025

3.  Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.

Authors:  Deeksha S Bali; Jennifer L Goldstein; Suhrad Banugaria; Jian Dai; Joanne Mackey; Catherine Rehder; Priya S Kishnani
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-01-17       Impact factor: 3.908

Review 4.  The molecular basis of familial dysautonomia: overview, new discoveries and implications for directed therapies.

Authors:  Berish Y Rubin; Sylvia L Anderson
Journal:  Neuromolecular Med       Date:  2007-11-06       Impact factor: 3.843

5.  Identification of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II.

Authors:  L Wan; C-C Lee; C-M Hsu; W-L Hwu; C-C Yang; C-H Tsai; F-J Tsai
Journal:  J Neurol       Date:  2008-05-06       Impact factor: 4.849

6.  Molecular genetics of late onset glycogen storage disease II in Italy.

Authors:  M G Pittis; M Filocamo
Journal:  Acta Myol       Date:  2007-07

7.  Atypical Infantile-onset Pompe Disease with Hypertrophic Cardiomyopathy.

Authors:  Jun-Jun Quan; Ling-Juan Liu; Tie-Wei Lyu; Xu-Pei Huang; Jie Tian
Journal:  Chin Med J (Engl)       Date:  2017-10-05       Impact factor: 2.628

8.  Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand.

Authors:  Lukana Ngiwsara; Duangrurdee Wattanasirichaigoon; Thipwimol Tim-Aroon; Kitiwan Rojnueangnit; Saisuda Noojaroen; Arthaporn Khongkraparn; Phannee Sawangareetrakul; James R Ketudat-Cairns; Ratana Charoenwattanasatien; Voraratt Champattanachai; Chulaluck Kuptanon; Suthipong Pangkanon; Jisnuson Svasti
Journal:  BMC Med Genet       Date:  2019-09-11       Impact factor: 2.103

9.  NGS-based expanded carrier screening for genetic disorders in North Indian population reveals unexpected results - a pilot study.

Authors:  Kanika Singh; Sunita Bijarnia-Mahay; V L Ramprasad; Ratna Dua Puri; Sandhya Nair; Sheetal Sharda; Renu Saxena; Sudha Kohli; Samarth Kulshreshtha; Indrani Ganguli; Kanwal Gujral; Ishwar C Verma
Journal:  BMC Med Genet       Date:  2020-11-02       Impact factor: 2.103

10.  Incidence of infantile Pompe disease in the Maroon population of French Guiana.

Authors:  Narcisse Elenga; Alain Verloes; Yajaira Mrsic; Célia Basurko; Roxane Schaub; Emma Cuadro-Alvarez; Rémi Kom-Tchameni; Gabriel Carles; Véronique Lambert; Rachida Boukhari; Aniza Fahrasmane; Anne Jolivet; Mathieu Nacher; Jean-François Benoist
Journal:  BMJ Paediatr Open       Date:  2018-01-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.